Rates of endophthalmitis before and after transition from povidone-iodine to aqueous chlorhexidine asepsis for intravitreal injection.
Can J Ophthalmol
; 2024 Feb 20.
Article
em En
| MEDLINE
| ID: mdl-38387861
ABSTRACT
OBJECTIVE:
To assess the rate of post-intravitreal injection endophthalmitis between 2 asepsis groups aqueous chlorhexidine 0.1% and povidone-iodine 5%.DESIGN:
Retrospective, observational cohort study.PARTICIPANTS:
Patients with infectious endophthalmitis post intravitreal injection (nâ¯=â¯58) at a single centre from July 2009 to July 2022.METHODS:
Retrospective chart review of all patients receiving intravitreal injections (216 593 injections) at a single centre over 14 years. Patients from July 2009 to February 2017 received povidone-iodine 5%, and patients from March 2017 to July 2022 received aqueous chlorhexidine 0.1%. Assessed characteristics of endophthalmitis cases included demographics, visual function, intervention type, and microbiological results.RESULTS:
The rate of endophthalmitis was comparable for povidone-iodine (1.45000) and aqueous chlorhexidine (1.35000) (pâ¯=â¯0.77). Vitreous cultures were negative for 55% of patients. Visual acuity (VA) outcomes did not differ between asepsis groups nor between culture positive/negative groups. Patients having vitrectomy (PPV) had worse final vision (pâ¯=â¯0.08) but there was no VA difference between early and late PPV.CONCLUSIONS:
Aqueous chlorhexidine 0.1% is a viable and safe alternative to povidone-iodine 5% for post-intravitreal injection endophthalmitis prophylaxis and may reduce ocular surface adverse events and discomfort.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
Can J Ophthalmol
Ano de publicação:
2024
Tipo de documento:
Article